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Abstract
Background: In past years, many researchers have sought canine visceral leishmaniasis (CVL) prevention through
the characterization of Leishmania antigens as vaccine candidates. Despite these efforts, there is still no efficient
vaccine for CVL control.
Methods: In the present study, we performed a pre-clinical vaccine trial using BALB/c mice to compare the effects of
the multicomponent LBSap vaccine with those of Leish-Tec® and Leishmune®. Blood was collected to determine the
frequency of peripheral blood cells and to evaluate hematologic and immunophenotypic parameters. Liver and spleen
samples were collected for parasitological quantification, and spleen samples were used to access the cytokine profile.
Results: When measuring total IgG and IgG1 anti-Leishmania levels after the third vaccination and L. infantum
challenge, it was evident that all vaccines were able to induce humoral immune response. Regarding the innate
immune response, increased levels of NK CD3-CD49+ cells were the hallmark of all vaccinated groups, whereas only the
Leish-Tec® group displayed a high frequency of CD14+ monocytes after L. infantum challenge. Moreover, CD3+CD4+ T
cells were the main circulating lymphocytes induced after L. infantum challenge with all evaluated vaccines.
Importantly, after L. infantum challenge, splenocytes from the Leishmune® vaccine produced high levels of IL-2,
whereas a prominent type 1 immune response was the hallmark of the LBSap vaccine, which presented high levels of
IL-2, IL-6, TNF-α, and IFN-γ. The efficacy analysis using real-time polymerase chain reaction demonstrated a reduction in
the parasitism in the spleen (Leishmune®: 64 %; LBSap: 42 %; and Leish-Tec®: 36 %) and liver (Leishmune®: 71 %; LBSap:
62 %; and Leish-Tec®: 48 %).
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Conclusions: The dataset led to the conclusion that the LBSap vaccination was able to induce immune and efficacy
profiles comparable with those of commercial vaccines, thus demonstrating its potential as a promising vaccine
candidate for visceral leishmaniasis control.
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Abbreviations: 15ASaline, 15 days after the third saline; 15AVac, 15 days after the third vaccination; 30AChal, 30 days after
experimental challenge; BV, Before the first vaccination; C, Control group; CVL, Canine visceral leishmaniasis;
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; Abbreviated as horseradish peroxidase; HRP, horseradish peroxidase;
LB, LBSap group; LBSap, Leishmania braziliensis antigen and saponin adjuvant; LM, Leishmune® group; LT, Leish-Tec® group;
natural killer cell; PCR, Polymerase chain reaction; SLcA, Soluble lysate of L. infantum antigen; VL, Visceral leishmaniasis
Background
Visceral leishmaniasis (VL), which is caused by Leishmania
infantum (syn. L. chagasi) and is also known as Kala-azar,
is a fatal infection if not treated successfully [1, 2]. Dogs
play an important role in parasite maintenance because
they are the main domestic reservoirs of L. infantum [3].
The best strategy to combat the spreading of disease would
be the use of a vaccine to control canine visceral leish-
maniasis (CVL). In recent years, several researchers have
devoted their efforts to finding an efficient alternative for
CVL prevention. However, no vaccine has proven to be
effective [4–7].
In 2014, two commercially available vaccines were
licensed by the Brazilian Ministry of Agriculture for use in
dogs: Leish-Tec® (Hertape S.A., Juatuba, Brazil), which con-
tains a recombinant amastigote stage–specific protein (rA2)
of different Leishmania species plus saponin as an adjuvant
[8–10], and Leishmune® (Zoetis, Campinas, Brazil), which
is composed of semi-purified fucose-mannose ligand (FML)
antigen glycoproteins from Leishmania donovani and
saponin [11–13]. However, in November 2014, the Brazilian
Ministry of Agriculture suspended the provisory license
granted to the Leishmune® vaccine for failing to fully meet
the requirements of a phase III vaccine clinical trial.
The choice of an appropriate experimental model is
critical to the success of studies in leishmaniasis
vaccinology. Several experimental models have been
used in vaccine trials, including dogs, hamsters and mice
[14, 15]. The murine models have several advantages
such as: easy handling, low cost, short time of experi-
mentation and wide availability of reagents for charac-
terizing the immune response [15]. In this sense, the
BALB/c mouse is a model highly used in preclinical
studies anti-CVL.
Given the importance of the evaluation of innate and
adaptive immune responses for understanding what
response is associated with resistance and parasite
control in VL-infected animals, this study aimed to
compare the Leishmune® and Leish-Tec® vaccines with
a patented vaccine candidate (LBSap) [16–18]. This
study provides evidence that LBSap is a potential
multicomponent vaccine for the prevention of VL
because it induces parasite control and a protective
immune response.
Methods
Animals, immunization protocol, and experimental
challenge
Female BALB/c mice (6–8 week-old) received subcutane-
ous injections (100 μl/dose) of the vaccines at intervals of
14 days for a total of three injections. The animals were
divided into four groups: Leish-Tec® (10 μg A2 and 50 μg
saponin/dose); Leishmune® (150 μg FML and 50 μg
saponin/dose); LBSap (60 μg Leishmania braziliensis anti-
gen and 50 μg saponin/dose); obtained according [16];
and Control group, inoculated with 0.85 % sterile saline.
The LBSap vaccine was registered at the Industrial
Property National Institute (Brazil) under patent number
PI 0601225-6 (February 17, 2006). Leish-Tec® and Leish-
mune® were purchased and diluted according to each
manufacturer at the time of immunization.
After 30 days of inoculum protocol, mice were chal-
lenged with 107 promastigotes of L. infantum at the
stationary phase in the lateral vein of the tail. Mice were
euthanized 30 days after experimental challenge. The
evaluations were performed at the following time points:
before the first vaccination (BV); 15 days after the third
saline [15ASaline] or vaccination (15AVac); and 30 days
after experimental challenge (30AChal). Blood was col-
lected to determine the frequency of peripheral blood cells
and to evaluate hematologic parameters (BV, 15AVac, and
30AChal). Liver and spleen samples were collected for
parasitological quantification, and spleen samples were
used to access the cytokine profile (30AChal).
All experiments were performed using groups of five ani-
mals per evaluation time in two independent batches. The
experiments showed similar results and the graphics are
representative of one experimental batch (n = 5 per batch).
Blood sample collection and differential leukocyte counts
The blood cell counts were determined using an
electronic haematology particle counter (BC2800Vet,
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Mindray, Hamburg, Germany). Differential leukocyte
counting was performed on Giemsa stained blood
smears, and a total of 100 cells were counted.
Humoral immune response
Antibody production was evaluated using a soluble lysate
of L. infantum antigen (MHOM/BR/1972/BH46) (SLcA)
and a conventional enzyme-linked immunosorbent assay.
Briefly, 96-well microplates (MaxiSorp®; Nalge Nunc Inter-
national, Rochester, NY) were coated with SLcA (at a con-
centration of 4.5 μg/ml) and after blocking with 2 %
casein, serum samples were added at a dilution of 1:40
and the plates were incubated at room temperature. After
a wash step, horseradish peroxidase (HRP)-conjugated
goat anti-mouse IgG heavy and light chain (HRP-conju-
gated, anti-mouse, lot A90116P-29; Bethyl Laboratories,
Montgomery, TX), anti-IgG1 (HRP-conjugated, anti-
mouse, lot A90105P-31; Bethyl Laboratories, Montgom-
ery, TX) or anti-IgG2a (HRP-conjugated, anti-mouse, lot
A90107P-34; Bethyl Laboratories, Montgomery, TX) were
added at dilutions of 1:3000, 1:2000, and 1:1000, respect-
ively. The wells were then washed, substrate and chromo-
gen (o-phenylenediamine; Sigma-Aldrich Co., St. Louis,
MO) were added, and the absorbance was read at 492 nm
on a Multiskan® MCC 340 (Labsystems, Helsinki, Finland)
automatic microplate reader.
Immunophenotyping of blood cells by flow cytometry
Immunophenotyping of blood cells was performed by flow
cytometry. The cell markers used were monoclonal
antibodies against CD14 (FITC anti-mouse CD14, clone
Sa2-8/E00166-204; e-Bioscience, San Diego, CA), CD3 (PE-
Cy5 anti-mouse CD3, clone 145-2C11/E060661630; e-
Bioscience, San Diego, CA), CD4 (FITC anti-mouse CD4,
clone GK1-5/E00078-133; e-Bioscience, San Diego, CA),
CD8 (APC anti-mouse CD8a, clone 53.6-7/E070561330; e-
Bioscience, San Diego, CA), CD19 (FITC anti-mouse CD19,
clone NB19-1/E00184-1630; e-Bioscience, San Diego, CA),
and CD49b (FITC anti-mouse CD49b, clone HMA2/
E00340229; e-Bioscience, San Diego, CA). The antibodies
were added to polystyrene tubes and 25 μl peripheral whole
blood collected in EDTA was added to each tube. After
homogenization in a vortex, the suspensions were incubated
for 30 min at room temperature in the dark.
After erythrocytes lysis, the samples were centrifuged.
The supernatant was discarded and the leucocytes were
washed with phosphate-buffered saline. Afterward, the leu-
kocytes were fixed with FACS FIX solution (10 g/l parafor-
maldehyde, 10.2 g/l sodium cacodylate, and 6.65 g/l
sodium chloride, pH 7.2). Flow cytometry measurements
were performed on a FACScalibur® instrument (Becton
Dickinson, Mountain View, CA). The program CellQuest
(Franklin Lakes, NJ) was used for data acquisition, and
Flow Jo Software (Flow Cytometry Analysis Software 7.6.;
Tree Star, Inc., Ashland, OR) was used for data analyses.
The representative flow cytometry analysis strategy on Flow
Jo Software can be seen in Additional file 1: Figure S1.
Nonspecific binding was monitored by using
fluorochrome-labeled isotypes to provide valid negative
controls. Autofluorescence was monitored by the use of a
negative control in which the cell suspension was incubated
in the absence of fluorochrome-labeled monoclonal anti-
bodies but in the presence of dilution and wash buffers.
Cytometric bead array
The spleen cells were prepared as previously described
elsewhere [19]. As specific stimulus we used the SLcA
(25 μg/ml). After the experiment the supernatant was col-
lected and stored in a freezer at -80 °C. The cytokine levels
were measured by Cytometric Bead Array (BD Biosciences,
San Jose, CA) according to the manufacturer’s recommen-
dations. Concentrations of each test sample in picograms
per milliliter (pg/ml) were calculated using FCAP software
array v.1.0.2 (BD Biosciences, San Jose, CA).
The cytokines profile was demonstrated by the index
of each cytokine obtained by dividing the values of the
SLcA-stimulated culture and the unstimulated culture
from the same animal. The index cytokine profile was
also used to stratify the mice as low or high cytokine
producers. For this analysis, the median of each cytokine
was obtained; the animals with measurements that were
above the median were considered high producers and
the information was plotted on the radar chart.
Real-time polymerase chain reaction
Real-time PCR was performed according to the protocol
described in [17]. The pair of primers used (forward: 5 -
TGT CGC TTG CAG ACC AGA TG-3 ; reverse: 5 -
GCA TCG CAG GTG TGA GCA C-3 ) was described
by [20] and targets the DNA polymerase gene of L. infan-
tum (GenBank: AF009147), which is a single-copy gene,
and amplifies a fragment of 90 bp. To verify the integrity of
the samples, the same procedure was performed for the
GAPDH gene (GenBank: AK168217.1). For amplification
of the GAPDH gene, the primers used were forward 5 -
GAA ACC TGC CAA GTA TG-3 and reverse 5 -
GGG AGT TGC TGT TGA AGT C-3 . Reactions were
processed and analyzed in an ABI Prism 7500-Sequence
Detection System (Applied Biosystems, Walthan, MA,
USA). The results were expressed as the number of amasti-
gotes per milligram of spleen and liver.
Statistical analysis
Statistical analyses were performed with GraphPad
Prism 6 software (Prism Software, Irvine, CA). Normal-
ity of the data was demonstrated using a D'Agostino-
Pearson normality test. One-way ANOVA followed by
Tukey’s test was used to analyze the inter-groups
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(Control × Leish-Tec® × Leishmune® × LBSap) and intra-
group differences (BV × 15AVac × 30AChal). Inter-group
differences were marked with letters corresponding to
each experimental group, as follows: “C” as compared
with the Control group; “LT” as compared with the
Leish-Tec® group; “LM” as compared with the Leish-
mune® group and “LB” as compared with the LBSap
group. Additionally, connecting lines are used to high-
light intra-group differences at different time points. All
differences were considered significant at P ≤ 0.05.
Results
All vaccines induced increases in total IgG, IgG1 and
IgG2a levels
Increases in total IgG, IgG1 and IgG2a were observed in
all vaccinated groups at 15Vac and 30AChal as compared to
BV (All statistical tests in this analysis had a P < 0.0001,
except for Leish-Tec® group - IgG2a [BV versus 15AVac: P
= 0.048]) (Fig. 1). It was also observed that IgG, IgG1 and
IgG2a increased in all immunized groups at 15Vac when
compared to the Control group (All statistical tests in this
analysis had a P < 0.0001, except in IgG2a Leish-Tec® (P =
0.002) versus Control group) (Fig. 1). Regarding the levels
of IgG2a, there was an increase in Leishmune® (P = 0.0002)
and LBSap (P = 0.003) groups at 15Vac as compared with
the Leish-Tec® group.
Both Leish-Tec® and LBSap presented increased counts of
lymphocytes after vaccination protocol
Differential leukocyte counts in peripheral blood leuko-
cytes profile in BALB/c mice immunized with the multi-
component LBSap vaccine, Leish-Tec® or Leishmune® were
carried out by conventional hematoscopy on Giemsa-
stained blood smear. Significant decreases in total neutro-
phils were observed at 15Vac in the Leish-Tec® (P = 0.050)
and in the LBSap (P = 0.020) groups as compared to BV.
LBSap group showed a decrease in total neutrophils at
15Vac as compared with the Leishmune® (P = 0.004) (Fig. 2).
Importantly, the total lymphocyte population displayed
high counts at 15Vac when Leish-Tec® (P = 0.048) and
Fig. 1 Comparative antigenicity by immunoglobulin analysis (total IgG, IgG1, and IgG2a) in serum. The x-axis displays the times at which the assays were
conducted (before first vaccination [BV], 15 days after third saline [15ASaline] or vaccination [15AVac] and 30 days after experimental L. infantum challenge
[30AChal]) using the different analyzed groups (n= 5 mice/group in two independent batches) (Control [□]; Leish-Tec® [ ]; Leishmune® [ ]; and LBSap
[killed L. braziliensis vaccine plus saponin; ■]). The y-axis represents the mean enzyme-linked immunosorbent assay absorbance values determined at
492 nm in serum samples diluted 1:40. The cut-off edge is demonstrated by the dotted line for total IgG (0.24), IgG1 (0.04) and IgG2a (0.11). Connecting
lines represent significant intra-group differences (P< 0.05) at the different time points. Inter-group differences at the same time point are marked by
letters (C: Control group, LT: Leish-Tec® group, LM: Leishmune® group, LB: LBSap group)
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LBSap (P = 0.008) were analyzed as compared to BV
(Fig. 2). At 15Vac the LBSap group had an increase in
total lymphocytes when compared with Leishmune®
group (P = 0.004) (Fig. 2). Regarding the red series, no
significant differences were observed (data not shown).
Regarding innate immune response, increased levels of NK
CD3-CD49+ cells were the hallmark of all vaccinated groups,
whereas only the Leish-Tec® group displayed a high
frequency of CD14+ monocytes after L. infantum challenge
Immunophenotypic analysis was carried out by flow cytom-
etry to characterize circulating innate immunity cells from
BALB/c mice immunized with the multicomponent LBSap
vaccine, Leish-Tec® or Leishmune®. An increase at 30AChal
for NK cells (CD3-CD49+) was observed in the Leish-Tec®
(P = 0.015), Leishmune® (P = 0.030) and LBSap (P = 0.050)
groups as compared to BV. Leish-Tec® (P = 0.005) and
Leishmune® (P = 0.016) also showed that this increase at
30AChal compared to 15Vac (Fig. 3). The evaluation of circu-
lating monocytes (CD14+) in the Leish-Tec® group showed
increased counts at 30AChal in comparison with both BV
(P = 0.019) and 15Vac (P = 0.003). The Leish-Tec® group
also showed an increase at 30AChal as compared to
Leishmune® (P = 0.0002), LBSap (P = 0.0004) and con-
trol groups (P = 0.0002) (Fig. 3). Leishmune® presented
high levels of CD14+ monocytes at 15Vac as compared
to BV (P = 0.001) and 30AChal (P = 0.002). Similar results
were observed in the LBSap group, which displayed
increased counts of CD14+ monocytes at 15Vac in com-
parison to 30AChal (P = 0.034) (Fig. 3).
CD3+CD4+ T cells were the main circulating lymphocytes
induced after L. infantum challenge for all evaluated vaccines
Immunophenotypic analysis was carried out by flow cytom-
etry to characterize circulating adaptive immunity cells
from BALB/c mice immunized with the multicomponent
Fig. 2 Differential leukocyte counts in peripheral blood leukocytes profile in BALB/c mice immunized with the multicomponent LBSap vaccine,
Leish-Tec® or Leishmune®. The x-axis displays the times at which the assays were conducted (before first vaccination [BV], 15 days after third saline
[15ASaline] or vaccination [15AVac] and 30 days after experimental L. infantum challenge [30AChal]) in the different analyzed groups (n = 5 mice/group in
two independent batches) (Control [□]; Leish-Tec® [ ]; Leishmune® [ ]; and LBSap [killed L. braziliensis vaccine plus saponin; ■]). The y-axis represents
the mean values (with standard deviations) of the frequencies of neutrophils, monocytes, eosinophils, and lymphocytes based on the hemogram.
Connecting lines represent significant intra-group differences (P < 0.05) at the different time points. Inter-group differences at the same time point are
marked by letters (LM: Leishmune® group and LB: LBSap group)
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LBSap vaccine, Leish-Tec® or Leishmune®. The Leish-Tec®
and Leishmune® did not alter the frequency of CD19+
B-cells (Fig. 4). In contrast, LBSap vaccination led to a
decrease in the frequency of B-cells at 15Vac (P = 0.031)
and 30AChal (P = 0.005) as compared to BV. More-
over, a decrease of B-cells was observed at 30AChal in
the LBSap group as compared to the Control group
(P = 0.014) (Fig. 4).
When evaluating total T-lymphocytes (CD3+), it was
observed that the Leish-Tec® group presented an increase
at 30AChal in comparison with BV (P = 0.028) (Fig. 4).
Furthermore, the LBSap group showed an increase in the
frequency of T-lymphocytes at 15Vac (P = 0.032) and
30AChal (P = 0.044) as compared to BV (Fig. 4).
In the Leish-Tec® group there was an increase of T-
helper lymphocyte (CD3+CD4+) at 30AChal as compared to
BV (P = 0.035) (Fig. 4). In the Leishmune® group, there
was an increase at 30AChal as compared to BV (P = 0.036)
and 15Vac (P = 0.044) (Fig. 4). Moreover, the Leishmune®
group also presented an increase at 30AChal as compared
to the Control group (P = 0.016). Similarly, the LBSap
group analysis showed sustained and increased counts of
CD3+CD4+ T cells at both 15Vac (P = 0.011) and 30AChal
(P = 0.009) as compared to BV (Fig. 4).
LBSap displayed a higher T-lymphocyte/B-lymphocyte
ratio in addition to an increased CD4+/CD8+ ratio after
both vaccination and L. infantum challenge
The analysis of the CD3+ T cells/CD19+ B-cells ratio re-
vealed an increase in the Leish-Tec® group at 30AChal in
comparison with BV (P = 0.002) (T/B ratio; Fig. 4). The
LBSap group showed an increase at 15Vac (P = 0.0002)
and 30AChal (P = 0.028) as compared to BV(Fig. 4).
Moreover, only the LBSap group showed an increase
in the CD4+/CD8+ T-cell subset ratio at 15Vac (P = 0.036)
and 30AChal (P = 0.014) as compared to BV (Fig. 4).
After L. infantum challenge, splenocytes from the
Leishmune® vaccine produced high levels of IL-2, but a
prominent type 1 immune response was the hallmark of
the LBSap vaccine, which presented high levels of IL-2,
IL-6, TNF-α and IFN-γ
Data analysis showed an increased IL-2 index in both
Leishmune® (P = 0.011) and LBSap (P = 0.028) groups as
compared to the Control group (Fig. 5, upper panel).
Furthermore, TNF-α analysis demonstrated high
levels in the LBSap group as compared to the Leish-
Tec® (P = 0.030) and Control (P = 0.011) groups (Fig. 5,
upper panel). Similar results were observed with IL-6,
which presented increased levels in the LBSap group
when compared to the Leish-Tec® (P = 0.006) and
Control (P = 0.003) groups (Fig. 5, upper panel).
We also observed an increase in the IFN-γ index in the
LBSap as compared to the Leish-Tec® (P = 0.048) and
Control (P = 0.026) groups (Fig. 5, upper panel). No sig-
nificant differences were observed regarding IL-10 and IL-
17A production (Fig. 5, upper panel). IL-4 production was
below the limit of detection of the test (data not shown).
Additional analysis of pro-inflammatory/regulatory
cytokine balance (IFN-γ/IL-10 index ratio) revealed a clear
Fig. 3 Immunophenotypic features of innate immunity (CD3-CD49b+ NK-cells and CD14+ monocytes) in BALB/c mice immunized with the multicomponent
LBSap vaccine, Leish-Tec® or Leishmune®. The x-axis displays the times at which the assays were conducted (before first vaccination [BV], 15 days after third
saline [15ASaline] or vaccination [15AVac] and 30 days after experimental L. infantum challenge [30AChal]) in the different analyzed groups (n= 5 mice/group in
two independent batches) (Control [□]; Leish-Tec® [ ]; Leishmune® [ ]; and LBSap [killed L. braziliensis vaccine plus saponin; ■]). The y-axis represents the mean
values (with standard deviations) of the frequency values in the lymphocytes or monocytes gate. Connecting lines represent significant intra-group
differences (P<0.05) at the different time points. Inter-group differences at the same time point are marked by letters (C: Control group, LT: Leish-Tec® group,
LM: Leishmune® group, LB: LBSap group)
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picture that all three vaccines [Leish-Tec®(P = 0.048),
Leishmune® (P = 0.036) and LBSap (P = 0.050) as com-
pared to the Control group] were able to trigger a cytokine
balance shifted toward a pro-inflammatory pattern, with
index ratio approximately twice higher for IFN-γ than
IL-10 (Fig. 5, upper panel).
In addition, the frequency of the overall cytokine pro-
duction was further evaluated by determining the
proportion of high producers that were displayed on
radar charts (Fig. 5, bottom panel). The Control group
demonstrated low numbers of high producers of pro-
inflammatory cytokines, and 50 % of animals presented
as high producers of IL-10 (Fig. 5, bottom panel).
Additionally, the Leish-Tec® group displayed a low fre-
quency profile with high producers of pro-inflammatory
and regulatory cytokines, although approximately 50 %
Fig. 4 Immunophenotypic analysis of adaptive immunity (CD19+ B-cells; CD3+, CD3+CD4+ and CD3+CD8+ T-cells; T/B ratio and CD4+/CD8+ ratio in BALB/c
mice immunized with the multicomponent LBSap vaccine, Leish-Tec® or Leishmune®. The x-axis displays the times at which the assays were conducted
(before first vaccination [BV], 15 days after third saline [15ASaline] or vaccination [15AVac]] and 30 days after experimental L. infantum challenge [30AChal]) in
the different analyzed groups (n= 5 mice/group in two independent batches) (Control [□]; Leish-Tec® [ ]; Leishmune® [ ]; and LBSap [killed L. braziliensis
vaccine plus saponin; ■]). The y-axis represents the mean (with standard deviations) of the frequency values in the lymphocytes gate. Connecting lines
represent significant intra-group differences (P< 0.05) at the different time points. Inter-group differences at the same time point are marked by letters
(C: Control group, LM: Leishmune® group, LB: LBSap group)
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Fig. 5 (See legend on next page.)
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of animals showed high IFN-γ production. Moreover,
the Leishmune® group revealed a pro-inflammatory
profile with approximately 50 % of animals being high
producers of IL-6, TNF-α, IFN-γ, and IL-17, in addition
to basal levels of IL-10. Furthermore, the hallmark of the
LBSap group indicated a prominent type I immune
response with a great frequency of animals (range, 60–
90 %) displaying high production of IL-6, TNF-α, IFN-γ,
and IL-17; approximately 50 % of animals showed high
IL-10 production (Fig. 5, bottom panel).
Leishmune® vaccination led to a reduction in parasite
load in the spleen, whereas Leishmune® and LBSap
presented low parasitism in the liver
As shown in Fig. 6 (upper panel), a 64 % reduction of
amastigotes in the spleen was observed in the Leishmune®
group (P = 0.034) when compared with the Control group.
Moreover, regarding the spleen parasite burden, there was
a decrease of 36 % in the Leish-Tec® group and 42 % in
the LBSap group (Fig. 6, upper panel).
Regarding parasite burden in the liver (Fig. 6, bottom
panel), there was a reduction of 71 % in the Leish-
mune® group (P = 0.004) and of 62 % in the LBSap
group (P = 0.036) when compared with the Control
group. Additionally, the Leish-Tec® group experienced
a decrease of 42 % in parasite burden in the liver (Fig. 6,
bottom panel). Interestingly, a parasite load reduction
of 23 % in the Leishmune® group was observed as com-
pared with the Leish-Tec® group (P = 0.044) (Fig. 6,
bottom panel).
Discussion
In the past years, several efforts have been made to
improve the scientific knowledge regarding the immuno-
logical tools to control CVL, mainly focusing on the
characterization and test of distinct Leishmania-derived
antigens as vaccines and candidates for VL control.
Regardless of these efforts, there are still relevant gaps
about the immunological mechanism of protection
triggered by distinct vaccines and novel immunobiologi-
cal candidates for VL control. Such information would
provide insights to improve the effectiveness of VL
immunoprophylaxis [4, 21].
(See figure on previous page.)
Fig. 5 Overall proinflammatory and regulatory cytokine patterns secreted by splenocytes from BALB/c mice immunized with the multicomponent
LBSap vaccine, Leish-Tec® or Leishmune®. In the upper panel, the x-axis displays the index (SLcA stimulated culture/unstimulated culture) of each
analyzed cytokine (IL-6, TNF-α, IL-2, IFN-γ, IL-10, IL-17A) 30 days after experimental L. infantum challenge in the different analyzed groups (n = 5
mice/group in two independent batches) (Control [□]; Leish-Tec® [ ]; Leishmune® [ ]; and LBSap [killed L. braziliensis vaccine plus saponin; ■]).
The y-axis represents the mean values (with standard deviations) of the stimulation index of analyzed cytokines. Significant inter-group differences
are marked by letters (C: Control group and LT: Leish-Tec® group). The bottom panel displays radar charts of proinflammatory and regulatory
cytokines from splenocyte supernatant culture. Each axis displays the proportion of high-producing cytokines in the following groups (n = 5
mice/group in two independent batches): Control (□); Leish-Tec® ( ); Leishmune® ( ); and LBSap (killed L. braziliensis vaccine plus saponin; ■)
Fig. 6 Comparative parasite burden in spleen and liver samples
determined 30 days after experimental L. infantum challenge in
BALB/c mice immunized with the multicomponent LBSap vaccine,
Leish-Tec® or Leishmune®. The x-axis displays the different analyzed
groups (n = 5 mice/group in two independent batches): Control (□);
Leish-Tec® ( ); Leishmune® ( ); and LBSap (killed L. braziliensis vaccine
plus saponin; ■). The y-axis represents the mean values (with standard
deviations) of amastigote numbers per milligram of organ. The
percentage of parasitism reduction in relation to the Control
group is represented in each bar. Significant inter-group differences are
marked by letters (C: Control group and LT: Leish-Tec® group)
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The murine experimental model for Leishmania infec-
tion represents a useful tool to investigate aspects
related to parasite-host interactions and has significantly
contributed to the design of hypothesis of immune-
mediated mechanisms relevant to understand distinct
aspects of leishmaniasis as well as identified relevant ele-
ments associated with protective response in immuno-
prophilactic approaches. However, although the data
generated in murine models can be used to predict a hy-
pothesis relevant to other host species, it is important to
mention that discussion of mouse model-derived results
must be performed carefully, taking proper prudence to
avoid over interpretation. In this sense, the data gener-
ated in the present investigation must be further vali-
dated in complementary investigations performed in
dogs, since these hosts present particularities in their
immune response that are distinct from those observed
in mouse models and critical for protection against
Leishmania infection. Nevertheless, there are several
findings previously reported in murine models that were
further validated in dog hosts.
Efficient immunization against infectious agents re-
quires the participation of the innate immune response
[22]. In this study, we observed a neutrophil reduction at
15AVac with respect to the BV in Leish-Tec® and LBSap
groups and the re-establishments of population levels at
30AChal. The role of neutrophils in the Leishmania
infection is still not fully understood. It has been described
that neutrophils play a role in the establishment of infec-
tion as “Trojan horses” [23]. However, some authors
believe that the neutrophils can also be associated with
the parasite control during ongoing VL [24–26].
Immunophenotypic analysis showed an increase in
monocyte (CD14+) frequency in the Leish-Tec® (30AChal)
and Leishmune® groups (15AVac), despite the reduction
found in the LBSap group (15AVac). Increased amounts
of circulating CD14+ monocytes were associated with
asymptomatic disease compatible with parasite control
in VL [27] or high immunogenicity elicited by vaccin-
ation against CVL [16]. In fact, monocytes/macrophages
are also extremely important in performing phagocyt-
osis, killing pathogens through the respiratory burst, and
participating in the production of proinflammatory
cytokines [28]. All immunized groups displayed increase
in NK cell frequency, particularly after experimental
challenge (30AChal). It has been proposed that these cells
have the ability to induce IL-12 production, favoring
high levels of nitric oxide production, activation of
macrophages, and thus inducing leishmanicidal activity
and parasite control [29].
The innate and adaptive immune systems synergize to ac-
tivate and execute a protective immune response following
vaccination. However, the adaptive immune system allows
the host to generate both antigen-specific responses and
immunological memory, which have primary importance in
the effective response against pathogens [30].
Regarding the CD19+ B-lymphocyte levels, a reduction
in the LBSap group (15AVac and 30AChal) was observed. It
is possible to speculate that this reduction is related to the
migration of these cells to lymphoid organs such as the
spleen for polyclonal activation and antibody production,
as previously reported [16, 31]. In agreement with this
hypothesis, we observed high increases in IgG and IgG1
(15AVac and 30AChal) in all immunized groups, indicating
similar high antigenicity elicited by analyzed vaccines. Fur-
thermore, the Leish-Tec® group displayed lower IgG2a
production at 15AVac compared to BV and compared to
other vaccine groups. To date, there is no data in the lit-
erature using the Leish-Tec® commercial formulation in
mouse models. It has been reported that IgG2a is closely
related to the type I immune response and type 2 response
correlates with IgE and IgG1 [32, 33]. It has been pro-
posed that one advantage of Leish-Tec® is the fact that it
induces the production of anti-A2, but not anti-SLA anti-
bodies [10] that would allow the discrimination of immu-
nized from infected dogs. However, it has been shown
that Leish-Tec®-immunized dogs present IgG, IgG1 and
IgG2 reactivity to SLA antigen. In fact, using a large num-
ber of dogs (n = 39) at different times after vaccination,
Fernandes and colleagues have demonstrated that the IgG
seroconversion rate of Leish-Tec®-immunized dogs can
reach 59.5 %, as early as 21 days after the first dose and
54.8 % later on at 21 days after the second dose [34].
These findings corroborate the data observed in the
present investigation showing the ability of Leish-Tec®
vaccination to elicit the production of anti-SLA IgG.
Regarding the frequency of CD4+ T lymphocytes, we
observed increased levels in the Leish-Tec® (30AChal),
Leishmune® (30AChal) and LBSap (15AVac and 30AChal)
groups. Because the memory T cells are critical for indu-
cing protection against infections in the long-term [35],
high levels of these cells after the vaccine protocol and
experimental challenge may be associated with immune
cell-mediated protection. The CD4+ T-cell induction in
anti-VL vaccines has been associated with high protec-
tion levels due to the ability of these lymphocytes to pro-
duce IFN-γ and promote macrophage activation favoring
the leishmanicidal activity [35–37]. Additionally, it has
been reported that dogs vaccinated with LBSap showed
an increase in the frequency of circulating T cells and
their subsets (CD4+ and CD8+) after the immunization
protocol [16] and remains even after long-term experi-
mental challenge in dogs [18]. The continued increase in
the ratio of T-lymphocytes to B-lymphocytes (T/B ratio)
in both Leish-Tec® and LBSap groups, after experimental
challenge (30AChal), was associated with CD3+ T cells,
particularly CD4+ T cells, with a consequent reduction
in CD19+ B-cells. Moreover, we also observed an
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increased CD4/CD8 ratio at 30AChal in the Leish-Tec®
and LBSap groups that was related to the increased
frequency of CD4+ cells. The increased CD4/CD8 T-cell
ratio could favor parasite control, because CD4 T cells
have been associated with an immune cell-mediated pro-
tective mechanism [4, 16, 18, 36].
The IL-2 increase in Leishmune® and LBSap and the
increase in IL-6, TNF-α, and IFN-γ levels in LBSap may
have contributed to the protection found in the vacci-
nated groups.
In fact, the analysis of overall proinflammatory and
regulatory cytokine patterns, demonstrated by radar
charts, indicated a prominent type 1 immune response
(high producers of IL-6, TNF-α, IFN-γ, and IL-17) in the
Leishmune® group and especially in the LBSap group.
Additionally, Leish-Tec® presented a low frequency of
IL-10 producers, which should contribute to the proin-
flammatory microenvironment. It is noteworthy that an
effector immune response against VL, with the production
of mainly proinflammatory cytokines such as IFN-γ and
IL-12, is usually correlated with a type 1 response [38, 39].
In contrast, a predominantly type 2 immune response
with regulatory cytokines, such as IL-10 and IL-4, appears
to exacerbate the Leishmania infection [40, 41].
The parasitological data regarding the LBSap group
corroborate with recent studies indicating that dogs
immunized with this vaccine and challenged had a 54 %
reduction in parasite load in splenic tissue [18]. The Leish-
mune® vaccine showed the highest parasite control in both
spleen and liver. Previous studies demonstrated an 84.4 %
reduction in liver parasite load in BALB/c mice immunized
with FML plus saponin [42]. BALB/c mice immunized with
A2 administered with Propianibactrium acnes as adjuvant
and infected by L. donovani showed an 89 % reduction in
liver parasites [43].
Together, our findings demonstrated evidences indicat-
ing the existence of particular phenotypic and functional
features elicited by the three vaccines. However, all three
vaccines are able to elicit relevant immunological changes
supportive of putative anti-Leishmania protective mecha-
nisms, such as a shift of cytokine balance towards higher
IFN-γ/IL-10 ratio. In this context, the LbSap vaccine trig-
gers an immune response comparable with other high
performance vaccines already developed to control L.
chagasi infection. Therefore, the LbSap vaccine represents
a putative candidate to be further improved to meet the
requirements of phase III clinical trials.
Conclusions
The dataset led to the conclusion that the LBSap vaccine
displayed immunological and parasitological profiles simi-
lar to other commercially available anti-CVL vaccines. In
this sense, our data indicate that the LBSap vaccine pre-
sented the following: high antigenicity with sustained
production of anti-Leishmania total IgG, IgG1, and IgG2a;
prominent cellular immune response displaying increased
levels of CD4+ T cells; and a proinflammatory cytokine pro-
file with high levels of Leishmania-specific IL-6, TNF-α,
and IFN-γ that contributed to a reduction in parasitism.
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